Featured Research

from universities, journals, and other organizations

Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients

Date:
July 18, 2011
Source:
American Association for Cancer Research
Summary:
The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.

The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.

Based on these study results, lead researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now know that these women should get trastuzumab and potentially chemotherapy, even if cancer spreads to the brain."

"Women with HER2-positive breast cancer have a reasonable chance of living a long time with their disease, and they should be given aggressive therapy where appropriate," added Brufsky, professor of medicine and associate director of clinical investigation at the University of Pittsburgh Cancer Institute.

Ten to 16 percent of women with advanced breast cancer develop central nervous system metastases, the researchers wrote in their study, published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Brufsky and colleagues used data from the registHER study to evaluate the incidence, potential risk factors and outcomes for patients with HER2-positive breast cancer. They evaluated how patients with HER2-positive breast cancer develop brain metastases, and followed them to examine what happens thereafter.

Of the 1,023 women newly diagnosed with HER2-positive metastatic breast cancer, 377 had central nervous system metastases.

Patients with central nervous system metastases were younger, and more likely to have hormone receptor-negative disease and higher disease burden compared with those whose cancer did not spread to the brain. In addition, for those patients without central nervous system metastases at initial diagnosis, cancer progressed to the brain about 13 months after diagnosis.

For those diagnosed with central nervous system metastases, treatment with trastuzumab, chemotherapy or surgery was each associated with a significant improvement in overall survival: trastuzumab 17.5 months vs. no trastuzumab 3.8 months; chemotherapy 16.4 months vs. no chemotherapy 3.7 months; and surgery 20.3 months vs. no surgery 11.3 months.

"It is surprising that chemotherapy/trastuzumab adds to these women's survival," Brufsky said. "We thought that the brain metastases would be dominant in this regard no matter what therapy."


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. M. Brufsky, M. Mayer, H. S. Rugo, P. A. Kaufman, E. Tan-Chiu, D. Tripathy, I. C. Tudor, L. I. Wang, M. G. Brammer, M. Shing, M. U. Yood, D. A. Yardley. Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clinical Cancer Research, 2011; 17 (14): 4834 DOI: 10.1158/1078-0432.CCR-10-2962

Cite This Page:

American Association for Cancer Research. "Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients." ScienceDaily. ScienceDaily, 18 July 2011. <www.sciencedaily.com/releases/2011/07/110718085322.htm>.
American Association for Cancer Research. (2011, July 18). Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2011/07/110718085322.htm
American Association for Cancer Research. "Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients." ScienceDaily. www.sciencedaily.com/releases/2011/07/110718085322.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins